CL2022001167A1 - Tratamiento de trastornos hepáticos - Google Patents
Tratamiento de trastornos hepáticosInfo
- Publication number
- CL2022001167A1 CL2022001167A1 CL2022001167A CL2022001167A CL2022001167A1 CL 2022001167 A1 CL2022001167 A1 CL 2022001167A1 CL 2022001167 A CL2022001167 A CL 2022001167A CL 2022001167 A CL2022001167 A CL 2022001167A CL 2022001167 A1 CL2022001167 A1 CL 2022001167A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- liver disorders
- disorders
- manifestations
- symptoms
- Prior art date
Links
- 208000019423 liver disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933277P | 2019-11-08 | 2019-11-08 | |
| US202063004403P | 2020-04-02 | 2020-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001167A1 true CL2022001167A1 (es) | 2023-02-10 |
Family
ID=75849579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001167A CL2022001167A1 (es) | 2019-11-08 | 2022-05-04 | Tratamiento de trastornos hepáticos |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4054567A4 (enExample) |
| JP (1) | JP2023501386A (enExample) |
| KR (1) | KR20220098168A (enExample) |
| CN (1) | CN114667142A (enExample) |
| AU (1) | AU2020380968A1 (enExample) |
| BR (1) | BR112022008639A2 (enExample) |
| CA (1) | CA3160445A1 (enExample) |
| CL (1) | CL2022001167A1 (enExample) |
| IL (1) | IL292459A (enExample) |
| MX (1) | MX2022005407A (enExample) |
| WO (1) | WO2021092474A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4259279A1 (en) | 2020-12-14 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors |
| TW202539702A (zh) * | 2024-03-08 | 2025-10-16 | 大陸商上海拓界生物醫藥科技有限公司 | 靶向ＩＮＨＢＥ的ＲＮＡｉ劑 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US20140187633A1 (en) * | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| MX2018011813A (es) * | 2016-03-28 | 2019-01-24 | Intercept Pharmaceuticals Inc | Medicina obtenida mediante la combinacion de agonista fxr y arb. |
| WO2018170173A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| US20210121493A1 (en) * | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| EP3844156A4 (en) * | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF LIVER DISEASES |
-
2020
- 2020-11-06 KR KR1020227018657A patent/KR20220098168A/ko not_active Withdrawn
- 2020-11-06 AU AU2020380968A patent/AU2020380968A1/en not_active Abandoned
- 2020-11-06 WO PCT/US2020/059522 patent/WO2021092474A1/en not_active Ceased
- 2020-11-06 CN CN202080077929.8A patent/CN114667142A/zh active Pending
- 2020-11-06 BR BR112022008639A patent/BR112022008639A2/pt not_active Application Discontinuation
- 2020-11-06 CA CA3160445A patent/CA3160445A1/en active Pending
- 2020-11-06 MX MX2022005407A patent/MX2022005407A/es unknown
- 2020-11-06 EP EP20886094.0A patent/EP4054567A4/en not_active Withdrawn
- 2020-11-06 JP JP2022526136A patent/JP2023501386A/ja active Pending
- 2020-11-06 IL IL292459A patent/IL292459A/en unknown
-
2022
- 2022-05-04 CL CL2022001167A patent/CL2022001167A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114667142A (zh) | 2022-06-24 |
| MX2022005407A (es) | 2022-05-24 |
| BR112022008639A2 (pt) | 2022-07-19 |
| WO2021092474A1 (en) | 2021-05-14 |
| IL292459A (en) | 2022-06-01 |
| CA3160445A1 (en) | 2021-05-14 |
| EP4054567A4 (en) | 2024-01-10 |
| KR20220098168A (ko) | 2022-07-11 |
| EP4054567A1 (en) | 2022-09-14 |
| AU2020380968A1 (en) | 2022-05-12 |
| JP2023501386A (ja) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| CO2020004301A2 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
| MX2021002305A (es) | Tratamiento de trastornos del higado. | |
| DOP2019000201A (es) | Compuestos inhibidores del vih | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| ECSP17073878A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| EA201692487A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| MX2017001656A (es) | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. | |
| NI201900088A (es) | Dendrímeros terapéuticos | |
| MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. | |
| IL290011A (en) | Ezh2 inhibition in combination therapies for the treatment of cancers | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| MX2019007892A (es) | Compuestos inhibidores de metaloenzimas. | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| MX2019007161A (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| CR20220071A (es) | Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2022006812A (es) | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. | |
| EA202191115A1 (ru) | Новые пиридазины | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. |